Utpal Koppikar net worth and biography

Utpal Koppikar Biography and Net Worth

Utpal Koppikar is the Chief Financial Officer of Atara Biotherapeutics, a position he has held since joining the company in June 2018. In this role, Utpal oversees Finance, Information Technology, and Investor Relations. Through a commitment to Atara’s mission of transforming the lives of patients with serious medical conditions, Utpal’s organization helps enable the advancement of our investigational medicines to commercialization.

Prior to his tenure with Atara, Utpal held several senior financial leadership positions at Gilead Sciences, including Vice President of Corporate and Operations Finance, in which he was responsible for R&D, corporate, G&A, process development and manufacturing, and strategic sourcing. During his time there, he led the three-year financial planning process and financial integration of Kite Pharma, upon that company’s acquisition by Gilead in October 2017.  Before that, Utpal played a key role as Gilead’s Vice President of Finance Europe, Middle East and Australia, in partnering with the commercial division for multiple product launches in the HIV and HCV franchises.

Prior to Gilead, Utpal served in multiple finance roles of increasing responsibility at Amgen. He began his career at Honeywell Aerospace (formerly AlliedSignal).

Utpal earned his B.S. in aerospace engineering at the University of Maryland and received a M.S. in aeronautical and astronautical engineering from Stanford University. He also holds an MBA in finance and marketing from The Anderson School at UCLA.

Away from work, Utpal enjoys spending time with his wife and two teenagers, traveling, and mentoring aspiring young aviators.

What is Utpal Koppikar's net worth?

The estimated net worth of Utpal Koppikar is at least $758,741.76 as of August 16th, 2022. Mr. Koppikar owns 197,589 shares of Atara Biotherapeutics stock worth more than $758,742 as of September 29th. This net worth evaluation does not reflect any other assets that Mr. Koppikar may own. Additionally, Mr. Koppikar receives a salary of $676,390.00 as CFO at Atara Biotherapeutics. Learn More about Utpal Koppikar's net worth.

How old is Utpal Koppikar?

Mr. Koppikar is currently 51 years old. There are 5 older executives and no younger executives at Atara Biotherapeutics. The oldest executive at Atara Biotherapeutics is Dr. Pascal Touchon D.V.M., Pres, CEO & Director, who is 59 years old. Learn More on Utpal Koppikar's age.

What is Utpal Koppikar's salary?

As the CFO of Atara Biotherapeutics, Inc., Mr. Koppikar earned a total compensation package of $2,137,953.00 in 2020. Mr. Koppikar earned a salary of $460,947.00, a bonus of $187,032.00, stock awards of $885,431.00, options awards of $597,073.00, and other compensation of $7,470.00.There are 3 executives that earn more than Mr. Koppikar. The highest earning executive at Atara Biotherapeutics is Dr. Pascal Touchon D.V.M., Pres, CEO & Director, who commands a salary of $1,110,000.00 per year. Learn More on Utpal Koppikar's salary.

How do I contact Utpal Koppikar?

The corporate mailing address for Mr. Koppikar and other Atara Biotherapeutics executives is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. Atara Biotherapeutics can also be reached via phone at (650) 278-8930 and via email at [email protected] Learn More on Utpal Koppikar's contact information.

Has Utpal Koppikar been buying or selling shares of Atara Biotherapeutics?

During the last quarter, Utpal Koppikar has sold $29,937.60 in Atara Biotherapeutics stock. Most recently, Utpal Koppikar sold 5,940 shares of the business's stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $5.04, for a transaction totalling $29,937.60. Following the completion of the sale, the chief financial officer now directly owns 197,589 shares of the company's stock, valued at $995,848.56. Learn More on Utpal Koppikar's trading history.

Who are Atara Biotherapeutics' active insiders?

Atara Biotherapeutics' insider roster includes Isaac Ciechanover (CEO), Jakob Dupont (EVP), Matthew Fust (Director), Utpal Koppikar (CFO), K. Murugan (SVP), Joe Newell (Insider), Thomas Peterffy (Chairman), Pascal Touchon (CEO), and Kristin Yarema (Insider). Learn More on Atara Biotherapeutics' active insiders.

Are insiders buying or selling shares of Atara Biotherapeutics?

During the last year, insiders at the biotechnology company sold shares 18 times. They sold a total of 118,341 shares worth more than $1,249,345.34. The most recent insider tranaction occured on August, 16th when CEO Pascal Touchon sold 14,806 shares worth more than $74,622.24. Insiders at Atara Biotherapeutics own 4.0 % of the company. Learn More about insider trades at Atara Biotherapeutics.

Information on this page was last updated on 8/16/2022.

Utpal Koppikar Insider Trading History at Atara Biotherapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2022Sell5,940$5.04$29,937.60197,589View SEC Filing Icon  
5/17/2022Sell5,582$5.32$29,696.24207,592View SEC Filing Icon  
2/7/2022Sell2,496$14.46$36,092.16View SEC Filing Icon  
11/16/2021Sell3,655$17.12$62,573.60View SEC Filing Icon  
8/17/2021Sell3,579$12.53$44,844.87161,369View SEC Filing Icon  
6/8/2021Sell5,820$14.06$81,829.20View SEC Filing Icon  
3/26/2021Sell1,761$14.58$25,675.38172,582View SEC Filing Icon  
2/8/2021Sell1,759$20.39$35,866.01View SEC Filing Icon  
8/18/2020Sell1,496$12.09$18,086.64133,530View SEC Filing Icon  
3/27/2020Sell1,827$9.17$16,753.59137,330View SEC Filing Icon  
2/6/2020Sell1,781$14.21$25,308.0172,282View SEC Filing Icon  
7/27/2018Buy2,000$36.80$73,600.00View SEC Filing Icon  
See Full Table

Utpal Koppikar Buying and Selling Activity at Atara Biotherapeutics

This chart shows Utpal Koppikar's buying and selling at Atara Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Atara Biotherapeutics Company Overview

Atara Biotherapeutics logo
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $3.62
Low: $3.60
High: $3.94

50 Day Range

MA: $4.05
Low: $2.85
High: $5.84

2 Week Range

Now: $3.62
Low: $2.83
High: $20.04


78,620 shs

Average Volume

1,855,308 shs

Market Capitalization

$341.58 million

P/E Ratio


Dividend Yield